UnitedHealthcare Tocilizumab Prior Auth Update | OpenPayer

Loading...

UnitedHealthcare Tocilizumab Prior Auth Update | OpenPayer

Coverage Criteria — Indication-specific and General Rules

Initial Therapy — Giant Cell Arteritis

Covered when ALL of the following are met

Giant Cell Arteritis initial: (1) Diagnosis of giant cell arteritis; (2) Patient is not receiving tocilizumab in combination with another systemic targeted immunomodulator for treatment of the same indication

Authorization issued for 12 months

Reauthorization — Giant Cell Arteritis

Reauthorization covered when ALL of the following are met

Giant Cell Arteritis reauth: (1) Documentation of positive clinical response to tocilizumab therapy; (2) Patient is not receiving tocilizumab in combination with another systemic targeted immunomodulator for treatment of the same indication

Authorization issued for 12 months

Initial Therapy — Rheumatoid Arthritis

Covered when ALL of the following are met

RA initial: (1) Diagnosis of moderately to severely active rheumatoid arthritis; (2) Inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs) (e.g., methotrexate, leflunomide, sulfasalazine); (3) Patient is not receiving tocilizumab in combination with another systemic targeted immunomodulator for treatment of the same indication

Authorization issued for 12 months

Reauthorization — Rheumatoid Arthritis

Reauthorization covered when ALL of the following are met

RA reauth: (1) Documentation of positive clinical response to tocilizumab therapy; (2) Patient is not receiving tocilizumab in combination with another systemic targeted immunomodulator for treatment of the same indication

Authorization issued for 12 months

Initial Therapy — PJIA

Covered when ALL of the following are met

PJIA initial: (1) Diagnosis of active polyarticular juvenile idiopathic arthritis; (2) Patient is not receiving tocilizumab in combination with another systemic targeted immunomodulator for treatment of the same indication

Authorization issued for 12 months

Reauthorization — PJIA

Reauthorization covered when ALL of the following are met

PJIA reauth: (1) Documentation of positive clinical response to tocilizumab therapy; (2) Patient is not receiving tocilizumab in combination with another systemic targeted immunomodulator for treatment of the same indication

Authorization issued for 12 months

Initial Therapy — SJIA

Covered when ALL of the following are met

SJIA initial: (1) Diagnosis of active systemic juvenile idiopathic arthritis; (2) Patient is not receiving tocilizumab in combination with another systemic targeted immunomodulator for treatment of the same indication

Authorization issued for 12 months

Reauthorization — SJIA

Reauthorization covered when ALL of the following are met

SJIA reauth: (1) Documentation of positive clinical response to tocilizumab therapy; (2) Patient is not receiving tocilizumab in combination with another systemic targeted immunomodulator for treatment of the same indication

Authorization issued for 12 months

Initial Therapy — SSc-ILD

Covered when ALL of the following are met

SSc-ILD initial: (1) Diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD); (2) Patient is not receiving tocilizumab in combination with another systemic targeted immunomodulator for treatment of the same indication

Authorization issued for 12 months

Reauthorization — SSc-ILD

Reauthorization covered when ALL of the following are met

SSc-ILD reauth: (1) Documentation of positive clinical response to tocilizumab therapy; (2) Patient is not receiving tocilizumab in combination with another systemic targeted immunomodulator for treatment of the same indication

Authorization issued for 12 months

General coverage and routing — Covered when clinician documentation and claim history meet program rules and routing:

Covered when clinician documentation and claim history meet program rules and routing:

Program approval conditions: UnitedHealthcare may approve initial or reauthorization requests based solely on previous claim/medication history, ICD-10 diagnosis codes, and claim logic; intravenous administrations are typically covered under the medical benefit; supply limits and/or step therapy may apply.

Use UnitedHealthcare Drug Policy for infusion-specific details; check plan for supply/step limits.

The policy clarifies that intravenous infusion administrations of tocilizumab are typically covered under the medical benefit. Providers should refer to the UnitedHealthcare Drug Policy for Tocilizumab for infusion-specific routing, billing, and coverage details because this subcutaneous-focused program does not govern IV-administered doses.

This policy reflects an administrative consolidation and product list update effective May 1, 2026. The program has been renamed to Tocilizumab, and Avtozma (tocilizumab-anoh) was added; references to Actemra and Tyenne were updated to Tocilizumab throughout the document.

When automated approval logic (for example, prior claim or medication history, ICD-10 diagnosis codes, or other claim-processing rules) does not support approval, requests may be denied. UnitedHealthcare may approve or deny initial and reauthorization requests based solely on those data elements, so providers should ensure claim history and submitted diagnosis codes accurately reflect the clinical scenario.

Coding and Benefit Routing

Prior Authorization / Benefit Routing Codesmixed

N/A	Document references prior authorization/notification but does not list specific CPT/HCPCS/NDC codes in this section.

What Providers Must Do / Watch For

Prior Authorization

Prior Authorization Required

Prior authorization required for subcutaneous tocilizumab (Actemra, Avtozma, Tyenne). Authorization criteria are indication-specific; authorization period is typically 12 months for approved indications.

Applies to subcutaneous formulations only
Authorization period: 12 months for approved indications

Prior Authorization

Prior Authorization / Notification May Be Required

Prior authorization or notification may be required; automated processes or benefit routing may direct IV formulations to the medical benefit per program rules. Check the UnitedHealthcare Drug Policy for Tocilizumab for IV administration billing and coverage details.

IV (intravenous) tocilizumab typically covered under the medical benefit
Refer to UnitedHealthcare Drug Policy for Tocilizumab for IV guidance

Background — Drug and Formulation Overview

Tocilizumab is an interleukin‑6 (IL‑6) receptor antagonist available in both intravenous and subcutaneous formulations. Subcutaneous products referenced in this program include Actemra, Tyenne, and the newly added Avtozma; the policy applies to subcutaneous formulations for labeled indications. IV infusions are generally routed to the medical benefit and are governed by the UnitedHealthcare Drug Policy for Tocilizumab. Labeled indications covered under the subcutaneous prior authorization program include moderately to severely active rheumatoid arthritis (after inadequate response to DMARDs), giant cell arteritis in adults, active polyarticular and systemic juvenile idiopathic arthritis in patients aged 2 years and older, and slowing pulmonary decline in systemic sclerosis-associated interstitial lung disease.

Definitions and Formulation Scope

Subcutaneous formulations

Applicable productsSubcutaneous tocilizumab formulations: Actemra (tocilizumab), Avtozma (tocilizumab-anoh), and Tyenne (tocilizumabaazg)

Program scopeProgram applies to subcutaneous formulations only (prior authorization/notification under the pharmacy benefit)

Indications includedApproved indications referenced for subcutaneous formulations: rheumatoid arthritis, giant cell arteritis, PJIA, SJIA, and SSc-ILD

Authorization periodAuthorization issued for 12 months when criteria are met

Routing noteIntravenous formulation is available but not covered by this subcutaneous program (see medical benefit for IV)

Intravenous infusion routing